Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors. An Open-Label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors.
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT03864042
Protocol ID: C4221003 (ARRAY-818-103)
PrintDownloadOpen Plain Language Summary Result: Click here